Recombinant zoster vaccine is associated with a reduced risk of dementia
6 hours ago
- #herpes zoster
- #vaccination
- #dementia
- Two doses of the recombinant zoster vaccine (RZV) are associated with a 51% lower risk of dementia in adults aged 65 and older.
- The study involved 65,800 RZV-vaccinated individuals and 263,200 unvaccinated matches, showing consistent risk reduction across age and racial/ethnic groups.
- Females exhibited a stronger risk reduction compared to males.
- After accounting for healthy vaccinee bias, RZV vaccination still showed a statistically significant lower risk of dementia.
- The study was conducted using Kaiser Permanente Southern California data, with findings presented at the Alzheimer’s Association International Conference 2025.
- The research was funded by GSK, with several authors declaring competing interests related to pharmaceutical funding.